Evidence map›Paper›PMID 26588360›Full record

ArticleJournal of medicinal chemistry2015

N'-3-(Trifluoromethyl)phenyl Derivatives of N-Aryl-N'-methylguanidines as Prospective PET Radioligands for the Open Channel of the N-Methyl-d-aspartate (NMDA) Receptor: Synthesis and Structure-Affinity Relationships.

Gregory R Naumiec, Kimberley J Jenko, Sami S Zoghbi, Robert B Innis, Lisheng Cai, Victor W Pike

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 16 citations in OpenAlex.

  1. A Review of Molecular Imaging of Glutamate Receptors.Molecules (Basel, Switzerland) · 2020
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gregory R NaumiecMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health , Building 10, Room B3 C346A, 10 Center Drive, Bethesda, Maryland 20892-1003, United States.
Kimberley J JenkoMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health , Building 10, Room B3 C346A, 10 Center Drive, Bethesda, Maryland 20892-1003, United States.
Sami S ZoghbiMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health , Building 10, Room B3 C346A, 10 Center Drive, Bethesda, Maryland 20892-1003, United States.
Robert B InnisMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health , Building 10, Room B3 C346A, 10 Center Drive, Bethesda, Maryland 20892-1003, United States.
Lisheng CaiMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health , Building 10, Room B3 C346A, 10 Center Drive, Bethesda, Maryland 20892-1003, United States.
Victor W PikeMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health , Building 10, Room B3 C346A, 10 Center Drive, Bethesda, Maryland 20892-1003, United States.
National Institute of Mental Health · USNational Institutes of Health · US

Funding

PET Radiopharmaceutical SciencesZIAMH002793 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PIKE, VICTOR W · 2009 to 2025
$69.8M
Translational Evaluation Of PET RadiotracersZIAMH002795 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI INNIS, ROBERT · 2009 to 2025
$32.0M
Intramural NIH HHS ZIA MH002793Intramural NIH HHS ZIA MH002795
6 · The paper itself

Abstract

N-Methyl-d-aspartate (NMDA) receptor dysfunction has been linked to several neuropsychiatric disorders, including Alzheimer's disease, epilepsy, drug addiction, and schizophrenia. A radioligand that could be used with PET to image and quantify human brain NMDA receptors in the activated "open channel" state would be useful for research on such disorders and for the development of novel therapies. To date, no radioligands have shown well-validated efficacy for imaging NMDA receptors in human subjects. In order to discover improved radioligands for PET imaging, we explored structure-affinity relationships in N'-3-(trifluoromethyl)phenyl derivatives of N-aryl-N'-methylguanidines, seeking high affinity and moderate lipophilicity, plus necessary amenability for labeling with a positron-emitter, either carbon-11 or fluorine-18. Among a diverse set of 80 prepared N'-3-(trifluoromethyl)phenyl derivatives, four of these compounds (13, 19, 20, and 36) displayed desirable low nanomolar affinity for inhibition of [(3)H](+)-MK801 at the PCP binding site and are of interest for candidate PET radioligand development.

Indexed as

1-NaphthylamineAnimalsBinding, CompetitiveCarbon RadioisotopesDizocilpine MaleateFluorine RadioisotopesGuanidinesIn Vitro TechniquesIon Channel GatingLigandsMethylguanidineNaphthalenesPhencyclidinePositron-Emission TomographyRadioligand AssayRadiopharmaceuticals1-NaphthylamineCarbon RadioisotopesDizocilpine MaleateFluorine RadioisotopesGuanidinesLigandsMethylguanidineNaphthalenesPhencyclidineRadiopharmaceuticalsReceptors, N-Methyl-D-Aspartate

Identifiers

PMID26588360
PMCPMC4980657
OpenAlexW2510852097

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.